Anticoagulation and antiplatelet management in gastrointestinal endoscopy: A review of current evidence

Table 22 Endoscopic submucosal dissection

Ref.	Year	Country	Study design	n	Procedure	Medication	Relative risk
Igarashi et al[56]	2017	Japan	Retrospective	367	Gastric ESD	Aspirin (continued)	Incidence of PPB 12.1%
Furuhata et al[115]	2017	Japan	Retrospective	15	Gastric ESD	Aspirin (continued or ceased 3-5 d before)	Incidence of PPB 6.7%
Sato et al[57]	2017	Japan	Retrospective	211	Gastric ESD	Aspirin (continued)	Incidence of PPB 5.7%
Kono et al[58]	2018	Japan	Retrospective	23	Gastric ESD	Aspirin (continued)	Incidence of PPB 21.7%
Arimoto et al[59]	2018	Japan	Retrospective	26	Colorectal ESD	Aspirin (continued)	No incidence of PPB
Oh et al[116]	2018	South Korea	Retrospective	94	Gastric ESD	Aspirin either: (1) Ceased 0-4 d before; (2) Ceased 5-7 d before	Incidence of PPB 12.8%
Harada et al[117]	2019	Japan	Retrospective	56	Gastric ESD	Aspirin (continued)	Incidence of PPB 10.7%
Nam et al[118]	2019	South Korea	Retrospective	31	Gastric ESD	Aspirin (ceased 7 d before)	Incidence of PPB 22.6%
Horikawa et al[119]	2019	Japan	Retrospective	50	Gastric ESD	Aspirin (continued)	Incidence of PPB 2.0%

ESD: Endoscopic submucosal dissection; PPB: Post-procedural bleeding.